1. From the Departments of Cardiology (T.A.A., S.E.K.) and Acute Medicine (M.R.), Ullevaal University Hospital, Oslo, Norway; Institute of Internal Medicine (P.O.), Department of Cardiology, Haukeland University Hospital, Bergen, Norway; Novartis Pharma (T.A.H.), East Hanover, NJ; and the Division of Cardiovascular Medicine (S.J.), University of Michigan, Ann Arbor.